Compare Recursion Pharmaceuticals Inc (RXRX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while TotalEnergies SE trades at $82.04 (market cap $179.99B). The key difference: TotalEnergies SE is far larger — about 117.6× Recursion Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 5.22% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TTE | |
|---|---|---|
Market Cap | $1.53B | $179.99B |
Sector | Health | Energy |
52-Week High | $6.79 | $93.60 |
52-Week Low | $2.84 | $57.39 |
Enterprise Value | $946.50M | $214.14B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
TotalEnergies (TTE) trades at $83.53, up 2.63% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.99 and P/S of 0.96, with strong profitability margins. Recent Q1 2026 earnings beat expectations at $2.45 EPS, while analysts maintain a consensus Buy rating with $100 price target representing 20% upside potential.
TTE presents compelling value with conservative valuation and steady dividend payments, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Key risks include ongoing Middle East exposure and energy price volatility. The upcoming Q2 earnings report on July 23rd will be crucial for confirming the positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
